Evidence map›Paper›PMID 39252823›Full record

ArticleMedComm2024

Leveraging single-cell RNA-seq for uncovering naïve B cells associated with better prognosis of hepatocellular carcinoma.

Qingjia Sun, Rui Gao, Yingxin Lin, Xianchao Zhou, Tao Wang, Jian He

Abstract read
In one paragraph

Article in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qingjia SunDepartment of Otorhinolaryngology Head and Neck Surgery The China-Japan Union Hospital of Jilin University Changchun China.
Rui GaoState Key Laboratory of Systems Medicine for Cancer Center for Single-Cell Omics School of Public Health Shanghai Jiao Tong University School of Medicine Shanghai China.
Yingxin LinSchool of Mathematics and Statistics The University of Sydney Sydney Australia.
Xianchao ZhouState Key Laboratory of Systems Medicine for Cancer Center for Single-Cell Omics School of Public Health Shanghai Jiao Tong University School of Medicine Shanghai China.
Tao WangUniv Lyon, Univ Jean Monnet Saint-Etienne, INSA Lyon, Univ Lyon 2 Université Claude Roanne France.
Jian HeState Key Laboratory of Systems Medicine for Cancer Center for Single-Cell Omics School of Public Health Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID https://orcid.org/0000-0002-1426-7799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a typical highly heterogeneous solid tumor with high morbidity and mortality worldwide, especially in China; however, the immune microenvironment of HCC has not been clarified so far. Here, we employed single-cell RNA sequencing (scRNA-seq) on diethylnitrosamine (DEN)-induced mouse HCC model to dissect the immune cell dynamics during tumorigenesis. Our findings reveal distinct immune profiles in both precancerous and cancerous lesions, indicating early tumor-associated immunological alterations. Notably, specific T and B cell subpopulations are preferentially enriched in the HCC tumor microenvironment (TME). Furthermore, we identified a subpopulation of naïve B cells with high CD83 expression, correlating with improved prognosis in human HCC. These signature genes were validated in The Cancer Genome Atlas HCC RNA-seq dataset. Moreover, cell interaction analysis revealed that subpopulations of B cells in both mouse and human samples are activated and may potentially contribute to oncogenic processes. In summary, our study provides insights into the dynamic immune microenvironment and cellular networks in HCC pathogenesis, with a specific emphasis on naïve B cells. These findings emphasize the significance of targeting TME in HCC patients to prevent HCC pathological progression, which may give a new perspective on the therapeutics for HCC.

Indexed as

B celldiethylnitrosaminehepatocellular carcinomaprognosissingle‐cell sequencingtranscriptomics

Identifiers

PMID39252823
PMCPMC11381656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.